Deferasirox: the new oral iron chelator.
Indian Pediatr
; 2007 Aug; 44(8): 603-7
Article
ي En
| IMSEAR
| ID: sea-12387
ABSTRACT
Deferasirox is a new tridentate oral iron chelator developed by computer remodeling recently approved by FDA for children above 2 years. Phase II/III trials have demonstrated similar efficacy to desferrioxamine and better chelation efficiency. Adverse events were minor and growth remained unaffected. Data on cardiac iron chelation is limited although some studies have shown it comparable to deferiprone. The benefit to risk profile of deferasirox is favorable. This promising new drug might decrease the burden of subcutaneous or intravenous infusion improving compliance and hence the life expectation in thalassemic patients.
النص الكامل:
1
الفهرس:
IMSEAR
اللغة:
En
مجلة:
Indian Pediatr
السنة:
2007
نوع:
Article